Diep Tuan Tu 4

What Happened Diep Tuan Tu, Chief Development Officer of Skye Bioscience (SKYE), received a derivative award of 125,000 shares reported as acquired at $0.00 on 2026-02-06. The filing lists this as a grant/award (derivative), not a market purchase or sale, so no cash changed hands in the reported transaction.

Key Details

• Transaction date: 2026-02-06; Form 4 filed: 2026-02-09 (filed within required reporting window).
• Reported acquisition: 125,000 derivative shares at $0.00 (no purchase price reported).
• Shares owned after transaction: not specified in the information provided.
• Footnote: the stock option vests in equal monthly installments over a four-year period beginning January 19, 2026.
• Nature: Award/grant of a derivative security (option/award), not a sale or open-market purchase.

Context This was a compensation-related derivative grant that vests over time — common for executives and intended to align long-term interests with shareholders. It does not represent an immediate market purchase or sale; investors should treat awards differently from outright purchases when assessing insider conviction.